BCL2 and neoplasm: Minoo's study of 399 CRCs showed that TOPK could be a marker of tumor in colon cancer in combination with CDX2, CD44v6, CD44s, nuclear ß-catenin, pERK, APAF-1, E-cadherin, p21, and bcl2 [45].